Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, 110070, India.
Hepatol Int. 2018 Nov;12(6):552-559. doi: 10.1007/s12072-018-9901-y. Epub 2018 Oct 19.
The objectives of the study were to evaluate the prognostic value of APASL ACLF Research Consortium-Acute-on-chronic liver failure (AARC-ACLF) score against the current prognostic models in pediatric ACLF and to assess the role of pediatric modifications of AARC-ACLF score and chronic liver failure-sequential organ failure assessment (CLIF-SOFA) score.
All children between 1 and 18 years of age satisfying the APASL definition of ACLF were included in the study. All the prognostic scores were calculated retrospectively from hospital records. Outcome was assessed at days 28 and 90. Pediatric modifications of AARC-ACLF and CLIF-SOFA scores were evaluated.
Acute-on-chronic liver failure was seen in 86 (13.4%) of 640 children with chronic liver disease. Twenty-five (29.8%) children died, 7 (8.3%) underwent liver transplant and the remaining 52 (61.9%) survived with their native liver. Four prognostic models (AARC-ACLF, AARC-ACLF-Pediatric, CLIF-SOFA and CLIF-SOFA-Pediatric) had an AUROC greater than 0.9 for predicting poor outcome in pediatric ACLF. AARC-ACLF and CLIF-SOFA models were superior to other prognostic scores with a cutoff score of 11 or more predicting poor outcome. Pediatric modifications of AARC-ACLF and CLIF-SOFA scores were not superior to their original scores. Children with poor outcome had rising scores at day 4, whereas the scores were falling in those with good outcome.
AARC-ACLF and CLIF-SOFA models are superior to other prognostic scores in pediatric ACLF. The scores are dynamic and a patient with either of these scores ≥ 11 at admission and/or a rising score at day 4 has high likelihood of death and needs to be urgently listed for liver transplantation.
本研究旨在评估 APASL ACLF 研究联盟-慢加急性肝衰竭(AARC-ACLF)评分对儿科 ACLF 现有预后模型的预测价值,并评估儿科 AARC-ACLF 评分和慢性肝脏衰竭-序贯器官衰竭评估(CLIF-SOFA)评分的修正版的作用。
所有符合 APASL ACLF 定义的 1 至 18 岁儿童均纳入本研究。所有预后评分均从住院病历中回顾性计算。结局在第 28 天和第 90 天评估。评估儿科 AARC-ACLF 和 CLIF-SOFA 评分的修正版。
640 例慢性肝病儿童中,急性肝衰竭 86 例(13.4%)。25 例(29.8%)患儿死亡,7 例(8.3%)行肝移植,其余 52 例(61.9%)存活且保留自身肝脏。4 种预后模型(AARC-ACLF、AARC-ACLF-儿科、CLIF-SOFA 和 CLIF-SOFA-儿科)对儿科 ACLF 不良结局的预测 AUC 值均大于 0.9。AARC-ACLF 和 CLIF-SOFA 模型优于其他预后评分,截断值为 11 分或更高可预测不良结局。儿科 AARC-ACLF 和 CLIF-SOFA 评分的修正版并不优于原始评分。预后不良的患儿第 4 天的评分升高,而预后良好的患儿的评分下降。
AARC-ACLF 和 CLIF-SOFA 模型在儿科 ACLF 中优于其他预后评分。评分是动态的,入院时这些评分中任何一项≥11 分和/或第 4 天评分升高的患者死亡可能性较高,需要紧急进行肝移植。